Novo Nordisk A/S - Share repurchase programme
Bagsværd, Denmark, 23 December 2016 - On 28 October 2016, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 3 February 2016.
Under the programme initiated 28 October 2016, Novo Nordisk will repurchase B shares for an amount up to DKK 4.5 billion in the period from 28 October 2016 to 31 January 2017.
Since the announcement as of 19 December 2016, the following transactions have been made under the programme:
Number of B shares
Average purchase price
Transaction value, DKK
Accumulated, last announcement
11,396,705
2,687,522,430
19 December 2016
310,000
254.18
78,796,432
20 December 2016
285,000
254.51
72,536,308
21 December 2016
321,565
254.16
81,728,383
22 December 2016
255,000
253.68
64,688,389
Accumulated under the programme
12,568,270
2,985,271,942
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
Page 2 of 2
With the transactions stated above, Novo Nordisk owns a total of 45,667,252 B shares of DKK 0.20, corresponding to 1.8% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,550,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 3 February 2016. As of 22 December 2016, Novo Nordisk has repurchased a total of 43,743,607 B shares equal to a transaction value of DKK 13,485,030,388.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,300 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,Facebook,Twitter,LinkedIn,YouTube
Further information
Media:
Anne Margrethe Hauge
+45 4442 3450
amhg@novonordisk.com
Ken Inchausti (US)
+1 609 786 8316
kiau@novonordisk.com
Investors:
Peter Hugreffe Ankersen
+45 3075 9085
phak@novonordisk.com
Melanie Raouzeos
+45 3075 3479
mrz@novonordisk.com
Hanna Ögren
+45 3079 8519
haoe@novonordisk.com
Anders Mikkelsen
+45 3079 4461
armk@novonordisk.com
Kasper Veje (US)
+1 609 235 8567
kpvj@novonordisk.com
Novo Nordisk A/S published this content on 23 December 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 23 December 2016 18:23:05 UTC.
Original documenthttp://www.novonordisk.com/bin/getPDF.2067764.pdf
Public permalinkhttp://www.publicnow.com/view/B2FE1093C2FA08CCF3C55B8913EBC62994EDE395
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
NOVO NORDISK A/S 
